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Abstract 18 
The treatment of some high incidence human diseases is based on therapeutic cell 19 
killing. In cancer, this is mainly achieved by chemical drugs that are systemically 20 
administered to reach effective toxic doses. As an innovative alternative, cytotoxic 21 
proteins identified in nature can be adapted as precise therapeutic agents. For 22 
example, individual toxins and venom components, pro-apoptotic factors and 23 
antimicrobial peptides from bacteria, animals, plants and humans have been 24 
engineered as highly potent drugs. In addition to the intrinsic cytotoxic activities of 25 
these constructs, their biological fabrication by DNA recombination allows recruiting, 26 
in single pharmacological entities, diverse functions of clinical interest such as specific 27 
cell-surface receptor binding, self-activation and self-assembling as nanoparticulate 28 
materials, with wide applicability in cell-targeted oncotherapy and theragnosis. 29 
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Antitumoral drugs: molecular size, circulation and specificity 34 
Regenerative medicine aims at favouring cell adhesion, viability and spread under 35 
adverse physiological conditions. In contrast, therapies of cancer and inflammatory or 36 
autoimmune diseases (such as Crohn’s disease, lupus erythematosus and multiple 37 
sclerosis) are based on effective cell killing. In oncotherapy, the destruction of 38 
differentiated cancer cells decelerates tumor growth, while an efficient killing of 39 
cancer stem cells (still to be fully accomplished in a clinical context) is expected to 40 
control recurrence and metastasis, the primary causes of patient death [1]. 41 
Conventional cancer treatments are based on a wide spectrum of systemically 42 
administered small molecular weight chemicals (including alkylating agents, 43 
anthracyclines, microtubule inhibitors, antimetabolites, platinum-based agents, 44 
topoisomerase inhibitors, tyrosine kinase inhibitors and histone deacetylase inhibitors, 45 
among others). In absence of targeting, hepatic and renal damage and undesired 46 
toxicity over other healthy organs results in numerous life-threatening side effects 47 
(Figure 1), including bone marrow toxicity (anaemia, thrombocytopenia, neutropenia), 48 
nausea, vomiting, cardiotoxicity and immunosuppression leading to enhanced 49 
susceptibility to infectious diseases. As systemic toxicity restricts the doses to be 50 
administered, drugs do not reach the required local concentration for a fully effective 51 
activity [2]. The insufficient therapeutic effect is also related to the small molecular 52 
size of antitumoral drugs: drugs that are below the renal filtration cut-off (estimated to 53 
be between 5 and 7 nm, [3, 4]) are cleared by the kidneys, minimizing their amount in 54 
blood and their circulation time (Figure 1). Conjugation to polyethylene glycol (PEG, 55 
see Glossary) increases drug hydrophilicity, impairs uptake by reticuloendothelial cells, 56 
minimizes clearance by neutralizing antibodies and reduces renal filtration, globally 57 
enhancing the therapeutic effect [5]. However, not adding any targeting ability, 58 
PEGylation does not represent a significant improvement regarding side toxicities. 59 
Moreover, reduced circulation time and the absence of selective cell killing in 60 
conventional chemotherapeutics have pushed the field towards exploring nanoscale 61 
drug carriers [6], which are nanosized particles to which the drug is associated to form 62 
a drug nanoconjugate [7, 8]. These vehicles, because of their size scale [9], are thought 63 
to execute a dual role in (i) allowing the effective anchoring of sufficient ligands of 64 
tumoral surface markers for cell targeting and (ii) enlarging the whole conjugate size 65 
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over the renal cut-off value, to minimize renal filtration [10] (Figure 1).  66 
 67 
Cell-targeted and untargeted nanocarriers 68 
 69 
Regarding cell-targeted drug delivery, different types of targeting moieties induce 70 
selective accumulation in target tissue using cell surface molecules overexpressed in 71 
some cancer cell lineages (Box 1). Binding to these molecules usually promotes 72 
receptor-mediated endosomal uptake of the ligands and linked payloads. 73 
Internalization is favoured by regular multivalent display of ligands on nanoscale 74 
entities, what promotes multiple cell anchorage and favours endosome formation [11]. 75 
Aptamers, monoclonal antibodies (mAbs), antibody derivatives or mimetics and 76 
receptor specific peptidic ligands [12] have been explored as targeting agents [13]. 77 
Avidity (the strenght with which a non-covalent attachment to a target molecule 78 
occurs) and selectivity (the ability to recognize a very specific target cell or receptor 79 
among other cell types or receptor molecules) can be further enhanced by the use of 80 
multiparatopic [14] or multispecific [15] agents, that bind to different epitopes of a 81 
given cell surface marker or of several markers, respectively, by the recruitment of 82 
diverse ligands in the conjugate.  83 
When drugs are required to be relatively large [9], incorporating molecular carriers 84 
that are too big might render aggregation in lung and undesired clearance by  85 
macrhophages of the mononuclear phagocyte system acting in the liver (Kupffer cells) 86 
or spleen. This can be avoided by keeping the conjugate size above 7 nm but below 87 
100 nm (in the size range of most viruses [11]). The nanoscale character of drug-carrier 88 
nanoconjugates offers additional advantages, such as enhanced permeability and 89 
retention (EPR) effect and improved drug stability in vivo [10]. The transcellular pores 90 
and fenestrae in the tumor vasculature are estimated to measure up to 500 nm [16], 91 
what allows the passage of materials up to this size. Targeting agents are usually 92 
attached to the carrier (Figure 1). Of course, targeting can be directly conferred to the 93 
drug without any carrier by direct chemical coupling between the chemical and a cell 94 
surface receptor ligand. The chemical linker must remain stable during all extracellular 95 
phases of the delivery process [17], keep the drug functional and maintain the proper 96 
biodistribution conferred by the targeting agent [18]. Antibody drug conjugates (ADCs, 97 
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Box 2), using mAbs as drivers, are the best representatives of this category of 98 
complexes. The antibody counterpart passively confers a nanoscale size (mostly under 99 
10 nm), but usually only monovalent or divalent binding to the target cell.   100 
Many categories of materials (dendrimers, metals, polymers, carbon nanotubes, and 101 
proteins, among others) are being explored as partners in drug nanoconjugates. Most 102 
of them, being highly stable and poorly biocompatible, generate reasonable concerns 103 
about their intrinsic toxicity, challenging both patient and environment safety [6]. In 104 
this context, proteins, as biocompatible macromolecular materials, are especially 105 
appealing as drug partners. Protein production in cell factories is undertaken by fully 106 
scalable, environmentally friendly and reliably tested procedures, and since the 107 
approval of insulin by FDA in the early 80’s, recombinant DNA technologies for protein 108 
engineering and production have been extensively developed [19]. Most protein-drug 109 
conjugation methods are based on lysine-amine and cysteine-thiol coupling by amine-110 
activated ester/carboxilic acid, and thiol-maleimide chemistries respectively. The use 111 
of non-natural amino acids (oxime ligation, azide-alkyne cyclization) or enyme assisted 112 
ligation (sortase A, transglutaminase, glycan remodeling) [20, 21] is also common. A 113 
paradigm of how proteins are incorporated as partners of small molecular drugs, to 114 
enhance size and stability, is Abraxane (Nab-Paclitaxel), first FDA-approved for breast 115 
cancer in 2005. Abraxane is a nanostructured complex (sizing 130 nm, [22]) formed by 116 
non-covalent hydrophobic interaction and high-pressure homogenization of human 117 
albumin and paclitaxel. This results in a nanoparticle colloidal suspension [23] used in 118 
metastatic breast, pancreatic and non-small lung cancers. Similar approaches are 119 
represented by Nab-rapamycin, that incorporates rapamycin to albumin and is 120 
undergoing clinical trails for refractory bladder cancer, and by Xyotax (paclitaxel-121 
polyglumex), a nanometric polymer of polyglutamate conjugated to paclitaxel, in 122 





Figure 1. A. The chemotherapy of cancer is commonly approached by the use of low 126 
molecular weight chemicals (red symbols and dots), exhibiting generic cytotoxicity 127 
over tumoral and healthy cells. Their low molecular size (usually < 5 nm, linked to renal 128 
clearance) and lack of selectivity render an undesired biodistribution. This is associated 129 
to severe side effects and suboptimal drug concentration in tumoral tissues. The 130 
pharmacological linkage of these chemicals to nanoscale carriers (bottom, blue) and 131 
their functionalization with targeting agents (purple) minimize renal clearance of the 132 
nanoconjugates and increase local drug levels. Connecting the drug to carrier 133 
nanoparticles or to targeting agents are mechanistically independent strategies, which 134 
do not need to be necessarily coupled. As an example, ADCs (Box 2) consist of chemical 135 
drugs directly coupled to antibodies against tumoral cell surface targets. B. Diverse 136 
roles of proteins in oncotherapy formulations, either as drug assistant agents 137 
(providing nanoscale size and stability or targeting), or as drugs themselves with 138 
intrinsinc cytotoxic activities. According to the designed functionalities the protein 139 
drugs are presented in alternative constructions or formulations. 140 
 141 
Cytotoxic proteins 142 
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Many proteins themselves from diverse natural sources exhibit potent cytotoxic 143 
activities toward mammalian cells, through deleterious enzymatic activities or by 144 
precise interventions over the cell cycle. Snakes are a rich source of cytotoxic proteins 145 
for oncology and cardiovascular disorders [24]; marine snails, of ion channel blockers 146 
[25]; scorpions, of neurotoxins, antitumoral agents and ion channel blockers [26]; and 147 
spiders, of painkillers, inflammation and cardiovascular disorders [27]. Furthermore, 148 
plants [28] and bacteria [29] have provided a diversity of protein-based antitumoral 149 
agents. Botox (Allergan), the Clostridium botulinum neurotoxin A (also marketed as 150 
Dysport, Ipsen, and Xeomin, Merz Pharma), blocks the neuronal release of 151 
acetylcholine resulting in muscular paralysis [30]. As a paradigm of the wide 152 
applicability of toxic proteins, the FDA has approved this bacterial toxin to treat 153 
chronic migraines, abnormally intense sweating, strabismus, overactive bladder and 154 
muscle spasms, among other therapeutic applications (apart from the better known 155 
cosmetic uses in wrinkle reduction). In this context, venom components and toxins, 156 
antimicrobial peptides and pro-apoptotic factors emerge as powerful therapeutic 157 
candidates. In addition, antibodies directed to particular cell-surface targets, apart 158 
from being used as tools for selective delivery, might initiate themselves deadly 159 
signalling cascades, acting as indirect cytotoxic drugs. Many natural or modified forms 160 
of these proteins are in clinical trials or already FDA-approved for oncotherapy (Table 161 
1). Furthermore, the flexibility of proteins as tuneable macromolecules allows their 162 
functional and structural tuning to reach the desired nanoscale size and targeting [31], 163 
that might be achieved in modular, multidomain proteins by the appropriate 164 
combination of functional stretches [32, 33].  165 
 166 
Venoms 167 
Venoms are complex combinations of toxins, which are highly bioactive (cytotoxic) 168 
molecules and from which peptides and proteins are the most abundant components 169 
[34]. They act on exposed cells by diverse mechanisms that include cell cycle 170 
alterations, induction of apoptosis and necrosis [35], cell membrane depolarization 171 
[26], cell growth inhibition, cellular membrane disruption or JAK2/STAT3 172 
downregulation [36]. Numerous venom protein toxins have been produced in 173 
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recombinant forms (Table 2), thus revealing a very common modular architecture [37] 174 
that offers additional versatility in the engineering of these agents as multifunctional 175 
drugs (Figure 2).  176 
 177 
Plant toxins 178 
Individual toxins are found in plants, amphibians and microorganisms. Plant toxins are 179 
extremely potent molecules. Many of them (such as ricin, saporin, abrin, trichosanthin, 180 
bouganin and gelonin) fall in the category of ribosome inactivating proteins (RIPs), N-181 
glycosidases that depurinate a single adenine residue in the 23S/25S/28S rRNA stem-182 
loop, blocking protein translation and leading to cell death. Some RIP plant toxins such 183 
as trichosantin, exhibit an inherent preferential activity over cancer cells that blocks 184 
the PKC/MAPK signalling pathway and induces apoptosis [38]. Trichosanthin and 185 
related toxins are particularly interesting since they also inhibit HIV-1 multiplication, 186 
due to its capacity to cleave supercoiled double-stranded DNA to linear and nocked 187 
circular DNA [39, 40].  188 
 189 
Microbial and animal toxins 190 
Microbial toxins have been also adapted as drugs. Denileukin diftitox (ONTAK®) is an 191 
engineered, FDA-approved drug based on the Corynebacterium diphtheriae toxin fused 192 
to interleukin-2, that targets the toxin to leukaemia and lymphoma cells that display IL-193 
2 receptors [41]. The exotoxin A from Pseudomonas aeruginosa (PE) has been also 194 
produced through recombinant methodologies in different versions, which are under 195 
clinical trials to treat mesothelioma and leukemia [42, 43]. Among animal toxins, 196 
melittin, a 26-amino acid peptide, is the main component of bee (Apis mellifera) 197 
venom and shows a high membranolytic activity [35]. On the other hand, chlorotoxin is 198 
a scorpion peptide (from Leiurus quinquestriatus) able to bind selectively cancer cells 199 
through the matrix metalloproteinase-2 (MMP-2) and annexin-2 expressed in several 200 




Antimicrobial peptides 203 
 204 
Antimicrobial peptides (AMPs) are short protein stretches (2-9 kDa) that in the innate 205 
immune system of higher organisms act as a first line of defense against microbial 206 
infections. AMPs show avidity for negatively charged cell membranes and promote cell 207 
lysis through pore formation [45]. Some AMPs, called anticancer peptides (ACPs) 208 
selectively bind cancer cells inducing tumor apoptosis or necrosis [46, 47]. Some ACPs 209 
also inhibit tumor angiogenesis [48] and show immunomodulatory activities [49]. Most 210 
ACPs have human and animal origins but others have been isolated from peptide 211 
libraries or generated by de novo design.  212 
 213 
Pro-apoptotic proteins 214 
The apoptotic cell death program serves as a natural barrier to tumor development 215 
through the extrinsic apoptosis pathway,  activated by extracellular pro-apoptotic 216 
stimuli, and the intrinsic pathway, mainly controlled by the BCL-2 family of proteins 217 
consisting of  anti-apoptotic and pro-apoptotic members [50]. Pro-apoptotic proteins 218 
can be categorized into BH3-only proteins (BIM, BID, PUMA, NOXA, BAD, BIK, and HRK) 219 
that contain only one BCL -2 homology (BH) domain (BH3), and into multidomain 220 
proteins (BAX and BAK) with four BH regions (BH1, BH2, BH3 and BH4) [51]. BH3-only 221 
proteins are divided into activators and sensitizers [52]. Activators convert inactive 222 
BAX-BAK monomers into pore-forming proteins that assemble into oligomeric 223 
complexes in the mitochondrial outer membrane. Sensitizers displace activator BH3 224 
proteins from binding to anti-apoptotic members, leaving them free to bind and 225 
activate BAX/BAK [53]. The clinical value of pro-apoptotic proteins (and many AMPs as 226 
well) as drugs in oncology is enriched due to the human origin of these proteins, 227 
whose administration would not promote immunotoxicity usually associated to 228 
heterologous protein drugs.  229 
 230 
Monoclonal antibodies  231 
Monoclonal antibodies (mAbs) are used as drivers in targeted drug delivery but 232 
furthermore they can also induce antitumor effects by direct interaction with the 233 
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target protein [54]. Therefore, they represent the largest group of approved 234 
therapeutic proteins in oncology [55]. Most of them inhibit target receptors involved in 235 
tumor epithelial cell growth (like Her2, epidermal growth factor receptor-EGFR- or 236 
PDGFR-), but others inhibit tumor growth indirectly, by targeting ligands or receptors 237 
involved in tumor angiogenesis (VEGF-A, VEGFR-2). In addition, the fastest developing 238 
mAb drugs target cancer and immune (e.g. T-cell) cell molecules (CTLA-4, PD-1, PD-L1) 239 
to reactivate the antitumor immune cell function (Table 1). In comparison to 240 
untargeted chemotherapy, mAbs display a longer half-life, increased selectivity and 241 
reduced off-target effects. However, their limited extravasation and tumor acces 242 
promote fast development of tumor resistance and dose-limiting toxicities [56]. 243 
 244 
Engineering cytotoxic proteins as drugs  245 
Most cytotoxic proteins that are approved or under clinical development are not 246 
natural but modified versions with improved functionalities. Toxins and mAbs, of non-247 
human origins, are generically immunotoxic and require deimmunization-oriented 248 
engineering. On the other hand, gaining nanoscale organization through multimeric 249 
self-assembling and ideally conferring multivalent cell targeting (necessary for non-250 
antibody protein drugs) requires functional recruitment by the fusion of additional 251 
protein stretches to the active drug domain (Figure 2). Then, protein-based cytotoxic 252 
drugs usually show a modular architecture, a concept clearly illustrated by 253 
immunotoxins that are simple modular fusions of a toxin (for cytotoxicity) and an 254 
antibody or antibody fragment (Fab) (for cell targeting).  255 
 256 
Deimmunization 257 
Drugs based on non-human proteins contain antigenic peptides presented by MHC II 258 
molecules in antigen-presenting cells, in a process that activates T cells and stimulates 259 
B cells to generate anti-drug antibodies (ADAs). In addition, B-cells can be directly 260 
activated by multivalent ligands and B cell receptor cross-linking by foreign epitopes 261 
[57], which leads to ADA-mediated immune responses during drug treatments upon 262 
re-exposure. This event, occasionally inconsequential, may instead neutralize drug 263 
effectiveness or cause serious clinical adverse effects, which may terminate drug 264 
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development or lead it to be withdrawn from the market. In this context, 265 
hypersensitivity reactions have been reported [58], including acute infusion reactions 266 
occurring shortly upon re-exposure (e.g. Denileukin difitox, Brentuximab vedotin, 267 
Trastuzumab emtansine), hypersensitivity to unrelated allergens or the development 268 
of autoimmune diseases and flu-like reactions (Cergutuzumab Amunaleukin, 269 
Blinatumomab) associated with cytokine release (see Table 1). Less often, therapeutic 270 
proteins may be immunosuppressive leading to frequent and often severe adverse 271 
effects such as relapsed bacterial, viral or fungal infections (e.g. Y90-Ibritumomab 272 
tiuxetan, Etanercept, Aflibercept, Sitimagene cerdenovec and Talimogene 273 
laherparepvec) and complications such as virus-induced neoplasias.  274 
Early immunotoxins (that is, immune-targeted toxins, see below) lacked sufficient 275 
therapeutic window since presenting dose-limiting toxicity, they induced the life- 276 
threatening vascular leak syndrome (edema, weight gain, hypoalbuminemia, and 277 
orthostatic hypotension) [59]. Precise protein engineering has been applied to reduce 278 
the immunogenicity of Pseudomonas aeruginosa and Diphtheria toxin catalytic 279 
fragments to be further incorporated to immunotoxins. The portions of these toxins 280 
that are not essential for cytotoxic activity or their processing have been deleted from 281 
the sequence, reducing the molecular weight of the cytotoxic drug component [58]. 282 
Moreover, immunotoxicity has been minimized by eliminating antigenic T and B cell 283 
epitopes, which limits immunogenicity and reduces the off-target effects that prevent 284 
repeated treatment cycles. Deimmunization of a Pseudomonas aeruginosa toxin 285 
fragment (PE38) has been achieved by introducing mutations in B- or T-cell epitopes 286 
without compromising antitumor potency, and deletion of the PE domain II which 287 
prevented the induction of vascular leak syndrome [60]. A truncated diphtheria toxin 288 
(DT390) has also been deimmunized by point mutations of surface-exposed highly 289 
hydrophilic amino acids (R, K, D, E, and Q) to eliminate B cell epitopes without lossing 290 
antitumor activity [61]. Third generation immunotoxins consisting of a humanized 291 
targeting moiety (e.g. a mAb, Fv or Fab) fused to a deimmunized cytotoxic domain of 292 
the toxin are currently entering clinical trials. mAbs tend to offer a higher therapeutic 293 
index (TI) than small molecule drugs, that is, a wider margin between effective and 294 
toxic doses. However, their protein nature and relatively large size may stimulate the 295 
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immune system, leading to various adverse effects (Table 1). Murine mAbs induce the 296 
fomation of human anti-mouse antibodies in patients, but protein enginnering efforts 297 
to humanize them have significantly reduced their immunogenicity [58].  298 
 299 
Simple fusion technologies 300 
Immunotoxins (Table 1) are made of catalytic fragments of highly cytotoxic plant or 301 
bacterial toxins bound to highly selective targeting mAbs, Fv or Fab fragments. They kill 302 
dividing and non-dividing cells by inhibition of protein synthesis, a unique mechanism 303 
of action that is synergistic in combination with genotoxic chemotherapy as long as 304 
they show non-overlapping toxicities [62].  305 
An immunotoxin containing the diphtheria toxin A and B (DT) fragments fused to 306 
human IL-2 was marketed in 2001 as Denileukin Diftitox. It showed activity against 307 
several haematological malignancies, particularly cutaneous T-cell lymphoma (CTCL). 308 
However, the induction of vascular leak syndrome has moderated its use. Two 309 
additional immunotoxins are currently in clinical assays. A-dmDT390-bisFv(UCHT1) is a 310 
fusion protein of DT bound to Fv fragment of CD3 that targets T-cell and is active in 311 
CTCL [63] and DT2219ARL consists of a DT fragment bound to Fv fragments of CD19 312 
and CD22 active against B-lineage leukaemia or lymphoma. In addition, an 313 
immunotoxin consisting of PE38 fused to an anti-Tac subunit of IL-2R (LMB-2 (anti-314 
Tac[Fv]-PE38)) is currently in clinical trials, showing activity in several haematological 315 
neoplasias. RG7787 is composed of a Fab version of the SS1 antibody bound to a 316 
modified and less immunogenic PE fragment. Being active in animal models of 317 
mesotheliomas without significant adverse effects, it is expected to enter clinical trials 318 
soon. Moxetumomab Pasudotox is an anti-CD22 Fv fused to PE38 that is being 319 
evaluated for the treatment of CD22+ B-cell malignancies (e.g. hairy cell leukaemia, 320 
acute lymphoblastic leukaemia) which shows high response rates [60]. Antibody and 321 
antibody fragments have been also used for the targeting of non-toxin cytotoxic 322 
proteins such as pro-apoptotic factors.  An example is e23sFv-TD-tBID, which exploits a 323 
single-chain anti-HER2 antibody fragment to target BID [64].  324 
From a different approach, simple fusion technologies facilitate selective binding 325 
and/or cellular penetration of protein drugs by non-antibody protein agents such as 326 
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cell-penetrating peptides (CPPs). Pro-apoptotic peptides fused to the transactivator of 327 
transcription (TAT) of human immunodeficiency virus (TAT-Bid) [65], Antennapedia 328 
homeoprotein (Ant-BAKBH3) [66] or receptor binding domain of diphtheria toxin (Bad-329 
BTTR) [67] immediately activate untargeted apoptosis. Other driving peptides used as 330 
fusions are the gonadotropin releasing hormone (in form of GnRH-Bik, GnRH-BAK and 331 
GnRH-Bax) [68] and the human granulocyte-macrophage colony-stimulating factor (as 332 
hGM-CSF-Bad) [69]. Similar approaches applied to AMPs promote their internalization 333 
and mitochondrial-dependent apoptosis in the micromolar range. For example, the 334 
natural magainin II (MG2) fused to the CPP penetratin shows an IC50 in the micromolar 335 
range [70]. Even more appealing, MG2 linked to Bombesin recognizes a variety of 336 
human cancer cells and it shows specific and higher cytolytic effects compared to 337 
magainin alone in mice bearing MCF-7 breast tumor grafts [71]. Moreover, the de novo 338 
designed antimicrobial peptide KLAKLAK fused to a protein transduction domain (PTD) 339 
specifically kills endothelial cells [72] and the same peptide fused to HER-2-340 
targeting/neutralizing domain targets specifically HER-2 overexpressing cells in vitro 341 
and in vivo [73].  342 
More sophisticated versions of fusion technologies render modular recombinant 343 
proteins with diverse functionalities, through domains collected from different origins 344 
(Figure 2). Functional recruitment enhances the precision in the protein drug delivery 345 
process, enabling the polypeptide to perform accurate extra and intracellular activities. 346 
Most of these constructions are produced in very simple microbial cell factories (Table 347 
2) according to generic protein production technologies. 348 
 349 
Modular design of smart cytotoxic proteins  350 
Innovative antitumoral drugs still show severe side effects despite these engineering 351 
efforts (Table 1), what pushes towards further drug development based on safer 352 
principles. Two-partner fusion strategies discussed above (and most of the modular 353 
approaches too) enhance specificity but with still inappropriate nanoscale size and 354 
usually mono or divalent presentation of the targeting agent. Conventional nanoscale 355 
carriers used in nanomedicine, however, impose an undesirable burden of potentially 356 
toxic bulk material, that prompts to urgently explore vehicle-free nanostructured drugs 357 
13 
 
able to self-assemble [10]. In this emerging concept, self-assembling protein domains 358 
[74] can be used in modular constructs that self-organize as vehicle-free 359 
multifunctional protein drugs. For instance, some cationic peptides that are potent 360 
ligands of tumoral markers promote oligomerization of fusion proteins when 361 
combined with polyhistidines. As a paradigmatic example, the peptide T22, a ligand of 362 
CXCR4 (overexpressed in more than 20 human cancers), has been incorporated to 363 
histidine-tagged GFP constructions, which makes them self-organize into regular 364 
nanoparticles of between 12 and 60 nm that feature multivalent display of this peptide 365 
[75, 76]. Upon injection, these materials accumulate in tumoral tissues in absence of 366 
renal filtration [3]. The same principle has been applied to protein-only blood-brain-367 
barrier crossing nanoparticles [77] or to CD44-targeted nanoparticles for imaging or 368 
drug delivery in breast cancer [78]. The modular architecture of these fusions allows 369 
the incorporation of additional functional domains such as fusogenic peptides for 370 
enhanced endosomal escape [79]. By exploiting this principle, pro-apoptotic peptides, 371 
AMPs and microbial toxins have been instructed to self-assemble as cell-targeted 372 
nanoparticles ([80] and unpublished data). 373 
These strategies, together with the accumulated information on cytotoxic proteins, 374 
targeting agents, recombinant antibodies and other functional domains discussed 375 
above should allow a fast emergence of truly vehicle-free [10], cell-targeted cytotoxic 376 
nanomedicines, that based on functional recruitment, would necessarily involve 377 
multifunctional proteins as core components.  378 
 379 
Concluding remarks and future perspectives 380 
Targeting cytotoxic agents in cancer therapies is unquestionably an urgent demand. A 381 
plethora of approaches in this regard, using nanotechnological principles, has so far 382 
offered improved but still moderately competent drugs, mainly because of associated 383 
side toxicities. Empirical observations but also emerging bioengineering concepts point 384 
out to the design of protein-based cytotoxic drugs as promising alternatives. Proteins 385 
are extremely versatile macromolecules produced in recombinant cell factories, by 386 
cost-effective and fully scalable methods based on recombinant DNA technologies that 387 
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have been developed and optimized for almost 40 years. Contrarely to other biological 388 
macromolecules, nanostructured materials and chemicals, proteins can simultaneously 389 
execute, in single chain polypeptides, all the functions required in oncotherapy (see 390 
Outstanding Questions Box). These activities include efficient cell-targeting, potent 391 
cytotoxicity, self-assembling to reach the optimal nanoscale size and regular 392 
oligomerization for a multiple and ordered display of cell ligands. The incorporation of 393 
functional casettes by simple fusion approaches allows recruiting affinity tags for one-394 
step purification from cell factories, endosomolytic agents, protease target sites and 395 
intracellular trafficking domains, among others. Anticipable bottlenecks in the use of 396 
these biopharmaceuticals have been already observed and minimized during the 397 
development of the more than 400 protein drugs approved for human use. Protein 398 
enginnering offers valuable approaches to significant deimmunization or to the 399 
ablation of residual interactivity of a drug with non target organs (that might lead, for 400 
instance, to hepatic toxicity). In this context, an increasing number of protein-only 401 
prototypes have already confirmed the possibility to recruit high functional complexity 402 
in simple and safe biological entities. This is in contast to chemically heterogeneous 403 
nanoconjugates in which these functions are provided by the conjugation of different 404 
types of molecules, mostly resulting from non-biological fabrication. The expanding 405 
catalogues of functional modules (venoms, toxins, proaoptotic factors, AMPs and 406 
others) and cancer-relevant ligands together with emerging nanobiotechnological 407 
principles are expected to result in a new generation of antitumoral drugs that solely 408 
formed by recombinant proteins, might be competitive in the biopharma market for 409 








Figure 2. Modular organization of natural and representative engineered toxins. 414 
Natural toxins (blue set) usually show a modular architecture, illustrated here by the 415 
diphtheria toxin and by the P. aeruginosa exotoxin. Engineered versions (red set) have 416 
been adapted by modular protein engineering for functional recruitment as 417 
antitumoral drugs. Denileukin diftitox is an immunotoxin that delivers the diphtheria 418 
toxin (lacking the receptor binding domain, Ditox), targeting the IL-2 receptor [81]. 419 
D2C7-IT is an immunotoxin fusion consisting of single-chain variable-region antibody 420 
fragments (scFvs) of the monoclonal antibody D2C7 (D2C7-scdsFv). It targets both the 421 
wild-type form (EGFRwt) and the in-frame deletion mutant form (EGFRvIII) of 422 
epidermal growth factor receptor (EGFR), and is fused to domains II and III of the 423 
Pseudomonas exotoxin A (PE38KDEL) (D2C7-(scdsFv)-PE38KDEL [82]. DTATEGF is a 424 
bispecific immunotoxin based on a diphtheria toxin version (DT390), that binds both 425 
the EGF receptor (EGFR) and the urokinase-type plasminogen activator receptor 426 
(uPAR) [83]. In TRX-F3-Gel, the active, N-terminal segment of the plant toxin gelonin is 427 
targeted by F3, a ligand of nucleolin overexpressed in several tumor cell lineages. The 428 
thioredoxin (TRX)-H6 segment, used to enhance solubility and for purification upon 429 
recombinant production, is removed in vitro by the Tev protease [84]. In T22-BAK-H6, 430 
the human pro-apoptotic BAK is targeted by T22, a ligand of the cell-surface tumor 431 
marker CXCR4. The construct self-assembles as toroid nanoparticles by the combined 432 
presence of T22 and H6 (H6 also acting as purification tag. GFP allows the visualization 433 
of the material [80]. In T22-DITOX-H6, the C and T domains of the diphtheria toxin are 434 
presented in a similar way. The inserted furin cleavage site complements the internal 435 
one occurring between the C and T domains. In the endosome, the minimal cytotoxic 436 
segment of the construct, namely the C domain, is released upon endosomal 437 




Table 1. Representative examples of cytotoxic antitumoral protein drugs involving proteins, and the main side effects.  440 
The list is not exhaustive but includes the most explored/used agents. 441 
 442 
Drug  Marketed / 
on Trial 




Adverse Effects Reference 
CHEMICAL DRUGS     
Protein-stabilized 
nanoparticles  
    
Paclitaxel 
polyglumex  




Advanced non-small cell 
lung 
cancer, recurrent ovarian 
or colorectal cancer 




nab-Paclitaxel Abraxane Albumin-bound paclitaxel  
nanoparticle formulation 
Metastatic breast cancer,  
advanced non-small cell 








      
PROTEIN 
DRUGS 





     
Trastuzumab  
  
   
 
Herceptin Binds the extracellular 
domain of HER-2 
inhibiting the growth of 
Her2+ tumors 
 
Metastatic Her2+ Breast 
cancer, metastatic HER2+ 
Gastric cancer 
 
Cardiomyopathy,  heart 








   
Erbitux Binds EGFR, HER1 and c-
ErbB-1 inhibiting EGF 
binding to result in the 
induction of tumor cell 
apoptosis and inhibition 
of tumor growth  
 
K-Ras wild type 
metastatic colorectal 
cancer, head and neck 
cancer squamous cell 
carcinoma 
Cardiopulmonary arrest, 
Acneiform rash,  
Hypomagnesemia  
Infusion reactions, 
hypotension, loss of 
consciousness, shock, 
myocardial infarction, 





Bevacizumab  Avastin Binds VEGF-A, preventing 
its association with 
endothelial receptors, Flt-
1 and KDR to block  
endothelial proliferation, 
inhibiting angiogenesis 
and tumor  growth 
Metastatic cervical, 
colorectal or renal cell 
carcinomas, glioblastoma 
non-small cell lung 
cancer, epithelial ovarian 
cancer  
 
Gastrointestinal fístula and 
perforation, heart failure, 
haemorrhage hypertension, 
infusion reactions, 





Olaratumab  Lartruvo Binds PDGFR-α, 
preventing PDGF-AA, 
PDGF-BB, and PDGF-CC 
binding to block growth, 
and angiogenesis in 
sarcomas  
 
Soft tissue sarcoma  
 










Ipilimumab   Yervoy Binds CTLA-4 on cytotoxic 






adjuvant treatment of 
cutaneous melanoma  
 
Life-threatening immune-
mediated dermatitis, colitis 
and neuropathies, endocrine 
disorders, hepatotoxicity, 




Nivolumab   Opdivo Binds PD-1 receptor, 
blocking PD-L1 and PD-L2 
binding and restoring 




head and neck squamous, 
non-small cell lung and 





immune-mediated rash, type 
1 diabetes  
encephalitis  
colitis, thyroiditis, nephritis, 
hepatitis, 
pneumonitis, hypophysitis, 




     
Multispecific Antibodies 
    
Catumoxomab Removab Trifunctional bispecific 
(EpCAM & CD3) mAb 
binding tumor, T cells & 
Fc region to activate 
immunity 
Malignant ascites due to 
epithelial carcinomas 
Lymphopenia, abdominal 
pain, nausea, vomiting, 
diarrhoea, pyrexia, fatigue, 
chills, pain 
[87] 
Blinatumomab Blincyto Bispecific mAb that binds 
CD19 on B-cells and CD3 
on T cells  










In clinical  
trials 




Locally advanced and/or 
metastatic 
carcinoembryonic antigen 
positive solid tumors 






      
Pegylated Proteins 
    










Peginterferon Pegintron Pegylated Interferon Melanoma Neuropsychiatric disorders, 
bone marrow suppression, 
autoimmune disease, acute 
hypersensitivity 
NIH database 
https://clinicaltrials.gov/    
NCT00238329 
Immunotoxins 
     
A-dmDT390- 
bisFv(UCHT1) 
In clinical  
trials 
Anti-CD3-gamma-epsilon 
Fv fragments - modified 
form of diphtheria toxin 
Cutaneous T-cell 
Lymphoma 








In clinical  
trials 
Anti-CD22 mAb - modified 
Pseudomonas Exotoxin A 
fragment 
Relapsed and refractory 












In clinical  
trials 
Anti-alpha subunit IL-2R 
(CD25) mAb - modified 
Pseudomonas Exotoxin A 
fragment 
Hairy Cell leukemia, 
cutaneous  
T-cell lymphoma, chronic 
lymphocytic  leukaemia 










In clinical  
trials 
Mesothelin-binding SS1 
Ab - modified 
Pseudomonas Exotoxin A 
fragment 
Mesothelioma, Triple 




 vascular leak syndrome 
NIH database 
https://clinicaltrials.gov/    
NCT00024687 
Fusion Proteins 
     
Aflibercept Zaltrap VEGFR1&2 fragments - Fc 








Etanercept Enbrel Tumor necrosis factor 
receptor - 
Fc human IgG1 Fusion 
Protein 
Lymphoma and other  
malignancies 
Tuberculosis, fungal or viral 
infections, Injection site 
reaction 
NIH database 
https://clinicaltrials.gov/    
NCT00201682 
EphB4-HSA In clinical  
trials 
EphB4 extracellular 
domain fused to human 
serum albumin acting as 
decoy receptor 
Advanced urothelial, 
head and neck, non-small 
cell lung cancinomas and 
melanoma 
Steven-Johnson syndrome,  









Ontak Interleukin 2 - Diphtheria 
toxin  





hepatotoxicity,  visual loss, 




In clinical  
trials 
Bispecific scFv anti-CD19 
and anti-CD22 mAbs - 
modified form of 
diphtheria toxin Fusion 
Protein 
Relapsed/refractory  
B-cell lymphoma or 
leukaemia 
Peripheral edema and  
hypoalbuminemia 
NIH database 
https://clinicaltrials.gov/    
NCT02370160 
 443 
  444 
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Table 2. Representative examples of main cytotoxic proteins explored as antitumoral drugs, which are produced as recombinant versions in 445 
bacterial cell factories.  446 
 447 




Cancer tested References 
Pro-apoptotic       
BID Homo sapiens Activator: Interacts with high 
affinity to all anti-apoptotic 
proteins and directly activates 
Bax and Bak. 
 
Pro-apoptotic E. coli RosettaBlue 








PUMA Homo sapiens Activator: Interacts with high 
affinity to all anti-apoptotic 
proteins and directly activates 
Bax and Bak. 
 





          [80] 
BAD Homo sapiens Sensitizer: Interacts with anti-
apoptotic proteins. High 
affinity to Bcl-2 and Bcl-XL. 
 






BIK Homo sapiens Sensitizer: Interacts with anti-
apoptotic proteins. High 
affinity to Bcl-W and Bcl-XL. 
 












 colon cancer 
Toxin or venom 
compopnent 





Inhibition of EF-2 and 
therefore protein synthesis 
Pro-apoptotic E. coli BL21(DE3) 
Neuroblastoma, 
breast cancer and 
colon cancer 





Inhibition of EF-2 and 
therefore protein synthesis 








Chloride channels blocker 
Targeting and 
slightly apoptotic 





















induce apoptosis or necrosis 
but mechanism remains to be 
explored 
Anti-metastasis E. coli BL21 (DE3) and 
DH5α  
Liver cancer  [97] 
Colombistatins 2, 3, 











E. coli BL21 star Human skin 
melanoma 
[98] 




(plant) the cleavage of a single 
adenine residue in the 28S 
ribosomal RNA. 
activity  lymphoma 
Abrin Abrus precatorius 
(plant) 
Protein synthesis inhibition by 
the cleavage of a single 










Gelonin  Gelonium 
multiflorum 
(plant) 
Protein synthesis inhibition by 
the cleavage of a single 



















Box 1. Cell surface molecular targets in cancer.  448 
Tumoral cells overexpress on their surface different types of molecules (membrane 449 
receptors or markers), mainly proteins, that can serve as targets for drug anchorage 450 
and specific cell penetration through functionalization with specific ligands [13]. Earlier 451 
attempts to target cytotoxic drugs to cancer cells were aimed to fast dividing tumor 452 
cells, which leave tumor-initiating cells unattended. This might result in the 453 
consequent relapse a few months later, since these therapies increase the percentage 454 
of cancer stem cells (CSCs), that repopulate the tumor mass and that account also for 455 
metastases and resistance to treatment. Therefore, current research on cancer surface 456 
markers is mainly focused on CSCs. CSCs are defined by a combination of membrane 457 
markers or receptors common to different tumors, such as CD44, CD133, CD24, ESA, 458 
CXCR4, α2β1, and the multi-drug resistance MDR1 and ABCE2 [101, 102]. Some of them 459 
are particularly associated to specific types of cancer, in rapidly expanding catalogues 460 
that include CD44, CD24 and ALDH1 to breast cancer [103], CXCR4, LGR5, CLDN1, 461 
LY6G6D/F and TLR4 to colorectal cancer [104-106], CD151 to ovarian cancer [107] and 462 
Sox2, Oct4 and CD90 to lung cancer [108]. Since these markers are also expressed by 463 
progenitor non-tumor cells [109], the potential risk of side effects is not completely 464 
excluded. Therefore, it is a challenge to identify truly selective CSC markers, sufficiently 465 
overexpressed over progenitor cells to allow a safe expansion of the therapeutic 466 
window [106]. The development of multispecific of multiparatopic drugs or 467 
nanoconjugates should pave the way for a more specific delivery into tumoral CSCs.  468 
 469 
Box 2. The Antibody-drug conjugate concept; successes and limitations 470 
ADCs represent the earliest and simplest strategy to increase drug agressivity and 471 
selectivity against tumor cells. The first approved ADCs were Gemtuzumab ozogamicin 472 
(Mylotarg) in 2000, indicated for acute myeloid leukaemia, and Ibritumomab tiuxetan 473 
(Zevalin) and Tositumomab (Bexxar) in 2002 and 2003 respectively, both indicated for 474 
non-Hodgkin’s lymphoma. In ADCs, mAbs directed against cell surface markers (Box 1) 475 
are used as delivery agents for targeted systemic transport of chemically-coupled 476 
cytotoxic drugs, ideally inactive in the linked state. Microtubule inhibitors including 477 
maytansinoids (DM1/DM4) and auristatins (in form of monomethyl auristatin E or F; 478 
(MMAE, MMAF)) rapidly kill proliferating cells and are the most commonly used drugs 479 
in ADCs. Cytotoxicity is achieved by receptor-mediated internalization and drug release 480 
from lysosomal compartments. Under these premises, several generations of ADCs 481 
have been developed with increasing efficacies and clinical successes. Humanizing the 482 
mAb [110], improving linkers for maximal extracellular stability and intracellular drug 483 
release [111] and maximizing the molar ratio between drug and mAb [112] have 484 
resulted in improved immunoconjugates. However, they only marginally meet the 485 
expected clinical standards regarding efficiency and lack of side toxicity. Frequent life-486 
threatening toxicities are reported for ADCs [113], mainly due to highly potent payload 487 
drugs (required because only <1% of the injected ADC dose reaches the tumor [114, 488 
26 
 
115]). The most common adverse effect of ADCs includes MMAE-mediated bone 489 
marrow suppression leading to neutropenia, infections and sepsis, and DM4-induced 490 
ocular toxicity. MMAF-based conjugates induce thrombocytopenia and ocular toxicity 491 
whereas DM1 causes gastrointestinal toxicity, thrombocytopenia and neutropenia 492 
[113]. More than 70 ADCs are currently in clinical development, whereas 20 have been 493 
discontinued. As a paradigm of ADC development, Gemtuzumab ozogamicin delivers 494 
calicheamicin γ1 (one of the most cytotoxic antitumoral drugs so far identified) to 495 
CD33-expressing cells, through a humanized mAb to which the drug is linked by 496 
cleavable bonds. The use of Gemtuzumab was discontinued in 2010 because of the 497 
lack of improved efficacy regarding free drug and the important side effects, including 498 
severe myelosuppression, type III hypersensitivity, vein occlusion and death. Only two 499 
ADCs are currently on the market, Adcetris® (brentuximab vedotin, targeting 500 
monomethyl auristatin E to CD30+ cells and indicated for anaplastic large cell 501 
lymphoma and Hodgkin lymphoma) and Kadcyla® (Trastuzumab Emtansine, targeting 502 
Emtansine to HER2+ cells and indicated for breast cancer), and both are under strict 503 
pharmacovigilance. Slightly differently from ADCs, immunocytokine conjugates do not 504 
internalize into cells but instead localize their antitumor effect by stimulating the 505 
immune system. This is an active area of research with many new compounds entering 506 
clinical trials, such as (A-dmDT390-bisFv(UCHT1), Moxetumumab pasudotox, LMB-2 507 
(anti-Tac(Fv)-P38) and RG7787 SS1(dsFv)-PE38). Taking a fully different perspective, 508 
mAbs have been also explored for the tumoral delivery of more complex antitumoral 509 
entities. Among them, the CD20-targted delivery of Salmonella bacterials cells 510 
expressing prodrug-converting enzymes [116], is particularly interesting in the context 511 
of prodrug technologies, that pursue the enzyme-mediated local (cell-targeted) 512 
activation of the drug cytotoxicity [117].   513 
 514 
 515 




ADAs: anti-drug antibodies. They are generated during the immune response against 518 
an antigen present in a protein therapeutic after its administration to an organism  519 
ADC: antibody-drug conjugate. A chemically coupled complex between a drug and a 520 
targeting antibody that offers cell selectivity in the delivery process. 521 
ACP: anti-cancer peptide. Antimicrobial peptides that bind negatively charged molecules 522 
on the cancer cell membranes and selectively induce tumor apoptosis or necrosis. 523 
AMP: anti-microbial peptide. Often referred as host defense peptides, they are 524 
important players in the innate immune response. 525 
CSC: cancer stem cell. Cancer cells with capacity for self-renewal and differentiation 526 
into diverse cell types occurring in tumors. The subset of CSCs differs from more 527 
differentiated tumor cells in their unique capacity for of initiating and repopulating the 528 
tumor. 529 
DT: diphtheria toxin. An exotoxin secreted by the pathogenic bacterium 530 
Corynebacterium diphtheriae, the ethiological agent of diphtheria. 531 
EGFR: epidermal growth factor receptor. A transmembrane protein acting as a 532 
receptor for specific ligands, such as EGF and transforming growth factor-) that bind 533 
and activate cell signaling. 534 
EPR: enhanced permeability and retention effect. This is the local drug retention 535 
resulting from the highly permeable tumour vasculature combined with a poor 536 
lymphatic drainage.  537 
Fab: antigen-binding fragment. The antigen-interacting region of an antibody.  538 
Fv: variable (antibody) fragment. Variable loops of light and heavy chains responsible 539 
for antigen binding. 540 
FDA: Food and Drug Administration. A US federal agency responsible for protecting 541 
public health by ensuring safety and efficacy of drugs and biopharmaceuticals.  542 
mAb: monoclonal antibody. An antibody produced by the controlled culture of a clone 543 
of immune cells. 544 
MHC: major histocompatibility complex (MHC). A set of proteins displayed on the 545 
surface of cells that recognize foreign antigens to trigger its processing and the 546 
activation of an immune response. They are classified in class I and II. MHC class II 547 
proteins are expressed in dendritic cells, macrophages and B cells. 548 
MMAE: monomethyl auristatin E. A synthetic derivative of dolastatin, a peptapeptide 549 
inhibitor of tubulin polymerization with potent antimitotic activity isolated from a 550 
species of sea hare. 551 
MMAF: monomethyl auristatin F. A synthetic derivative of dolastatin, inhibitor of 552 
tubulin polymerization with lower antitumor activity than MMAE. 553 
28 
 
PDGFR: platelet-derived growt factor receptor. Cell surface receptors that bind and are 554 
activated for cell signaling by the family of PDGF ligands. 555 
PE: Pseudomonas aeruginosa exotoxin A. It is a bacterial secreted protein that inhibits 556 
the elongation factor-2 in the protein synthesis. 557 
PEG: polyethylene glycol. A polymer of ethylene oxide that once bound to 558 
nanoparticles inhibits their clearance by the immune system. 559 
RIP: ribosome-inactivating protein. A bacterial or a plant protein toxin that arrests 560 
protein synthesis in eukaryotic cells acting on the ribosome. 561 
scFv: single-chain variable fragment. A fusion between the variable regions of the 562 
heavy and light chains of an antibody, produced as a recombinant protein. 563 
TI: therapeutic index, an indication of drug toxicity referred to its therapeutic efficacy. 564 
TI is determined in animal models as the lethal drug dose for 50 % of the treated 565 
individuals (LD50) divided by the minimum effective dose, also for 50 % of the 566 
individuals (ED50). 567 
VEGF: vascular endothelial growth factor. A hypoxia-induced secreted protein that 568 
stimulates the formation of blood vessels in normal tissues and in tumors. 569 
VEGFR: vascular endothelial growth factor receptor: a cell surface receptor that is 570 
bound and activated by its ligand VEGF for cell signaling.  571 
 572 
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